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Somatostatin and somatostatin analogs 
SRIFt was described originally by Krulich et al. 
[l] as a factor present in hypothalamic extracts 
capable of inhibiting GH release by cultured rat 
anteriorpituitarycells.Brazeauetal. [2]characterized 
this factor as a cyclic peptide (SS14) consisting of 14 
amino acids. Several years later, a second bioactive 
form, an NHz-terminally extended somatostatin 
molecule, consisting of 28 amino acids (SS28), was 
isolated and characterized [3]. In mammals, both 
SS14 and SS28 originate from a 10.3 kDa prohormone 
called preprosomatostatin [4]. 
Somatostatin has an inhibitory action on a variety 
of physiological functions in different organ systems, 
including the hypothalamus, the anterior pituitary 
gland, the gastrointestinal tract, and the endocrine 
and exocrine pancreas [5]. In the brain, somatostatin 
may have a role in neurotransmission, both 
stimulatory and inhibitory [6,7]. On the basis of its 
widespread inhibitory actions, somatostatin may 
play a role in the treatment of human disease due 
to hyperfunction of the above organ systems. 
However, the clinical use of somatostatin was 
hampered because the native peptide had several 
disadvantages [S, 91. In particular, the need for 
continuous i.v. infusion due to its very short half- 
life in the circulation (< 3 min), its diversity of action 
(i.e. its potent inhibitory action on normal insulin 
secretion), and, finally, the rebound hypersecretion 
of hormones by normal tissues after 5514 infusion 
are major disadvantages [lo, 111. A logical step, 
therefore, was the development of structural analogs 
of somatostatin, not having the disadvantages of 
SS14 as described above. This research has led to 
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the synthesis of a great number of somatostatin 
analogs; thus far, three of them, octreotide (SMS 
201-995, Sandostatin), BIM-23014 (Lanreotide) and 
RC-160 (Octastatin, Vapreotide), are in clinical 
studies and/or use. Figure 1 shows the amino acid 
sequence of each of these analogs, in comparison 
with that of the native peptide. Until now, octreotide 
was the most widely used somatostatin analog for 
the treatment of human tumors [12]. 
Bauer et al. [ 131 originally developed via step-by- 
step modification of the conformationally stabilized 
central part of the SS14 molecule a series of highly 
potent octapeptide analogs, of which octreotide was 
the most active. This analog contains the sequence 
of residues 7-10 of SS14, Phe-Trp-Lys-Thr, essential 
for receptor binding, in which D-Trp was substituted 
for Trp (Fig. 1). Octreotide can be given sub- 
cutaneously, has a half-life of approximately 2 hr 
and turned out to be 45 times more active than SS14 
in inhibiting GH release in monkeys, 11 times more 
effective in inhibiting glucagon release, and most 
important, only 1.3 times more potent in inhibiting 
insulin release [13]. Thereafter, several analogs, 
related to octreotide, were synthesized and tested 
for their biological activity by Schally and co-workers 
[14,15]. They found that substitution of Phe and 
Thr by Tyr and Val, respectively, at positions 3 and 
6 resulted in a much higher potency for inhibition 
of GH secretion, but lower activity for inhibition of 
insulin and glucagon release in uiuo in rats. They 
also suggested that replacing Thr at position 8 with 
Trp may result in increased receptor affinity. This 
suggests that analogs containing the Tyr”/Va16 
substitution may be more specific for GH inhibition, 
and that there may be selectivity in the actions of 
octapeptide analogs. Both RC-160 and BIM-23014 
are Tyr3/Va16-containing somatostatin analogs; RC- 
160 also has Trp at position 8, and BIM-23014 
PNal at position 1. In addition to RC-160, BIM- 
23104 was chosen with the intention of finding an 
analog with little effect on insulin and glucagon 
secretion but with a more profound effect on GH 
secretion [16,17]. The above data also suggest the 
existence of multiple SS-R subtypes having selective 
affinities for structural analogs of somatostatin, and 
with a selective expression in different organ systems. 
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Fig. 1. Structures of somatostatin-14, octreotide, BIM-23014 and RC-160. 
This concept was further substantiated by the recent 
cloning of at least five different human SSTR 
subtypes (see below). As has been mentioned above, 
along with octreotide, RC-160 and BIM-23014, many 
other somatostatin analogs have been synthesized 
thus far. In this review, we will summarize the 
relevant literature data on binding of somatostatin 
analogs to human SSTR subtypes, as well as SSTR 
subtype expression in normal and tumorous tissues, 
and we will discuss the clinical role of somatostatin 
analogs in relation to SSTR subtypes. 
Somatostatin receptors in normal and tumorous 
tissues 
Along with the widespread biological actions of 
somatostatin, high-affinitySS-Rs havebeenidentified 
in all somatostatin target tissues. High-affinity 
somatostatin binding sites have been demonstrated 
in the anterior pituitary gland, the endocrine and 
exocrine pancreas, the gastrointestinal tract and the 
central nervous system. It has also become evident 
that many human neuroendocrine tumors, often 
originating from somatostatin target tissues, carry 
receptors for somatostatin [18,19]. Most of these 
human tumors containing a high density of SS- 
Rs have classical amine precursor uptake and 
decarboxylation (APUD) characteristics, and include 
pituitary adenomas, islet cell tumors, pheoch- 
romocytomas, paragangliomas, small cell lung 
cancers, medullary thyroid carcinomas and carcinoids 
[12]. In addition, other subgroups of tumors arising 
from dispersed neuroendocrine cells in organs like 
the breast, brain, colon and lung have been shown 
to carry SS-Rs both by in vitro studies using 
homogenate binding and receptor autoradiography, 
as well as by in vivo localization of primary tumors 
and their metastases by scintigraphy with the 
radiolabeled somatostatin analog octreotide. Kren- 
ning et al. [20] recently reviewed the results of the 
Rotterdam study of SSTR scintigraphy using [lz31- 
TyP]octreotide and [lllIn-DTPA-D-Phel]octreotide 
in 1000 patients. 
Somatostatin receptor subtypes 
Ligand-binding studies. By using the techniques 
of homogenate ligand binding and in vitro receptor 
autoradiography, evidence has been obtained for 
the existence of SS-R subtypes on the basis of a 
differential binding of native somatostatin (SS14 
and SS28) and of several structural analogs of 
somatostatin. Reubi et al. [21,22] and Tran et al. 
[23] showed that the somatostatin analog octeotide 
only partially displaced, although with high affinity, 
[1ZI-Tyr11]SS14 binding to rat cortical membranes. 
On the basis of their experiments, they suggested 
the existence of at least two somatostatin binding 
sites in the rat brain: an SS-R with high affinity for 
octreotide and an SS-R with low affinity for this 
somatostatin analog. Autoradiographic studies have 
also demonstrated the existence of SS-R subtypes in 
rat brain on the basis of distinct regional distribution 
patterns using different somatostatin analogs [24,25]. 
Also, functional studies point to the presence of SS- 
R subtypes in the brain. Inhibition of forskolin- 
stimulated adenylyl cyclase activity by somatostatin 
was observed in membrane preparations from the 
rat hippocampus and striatum but not from 
the substantia nigra. Moreover, octreotide solely 
inhibited adenylyl cyclase activity in the preparations, 
while SS14 also stimulated adenylyl cyclase activity 
at micromolar concentrations [26], 
By using SS-R autoradiography, a differential 
binding pattern of SS14 or SS28 on the one hand 
and of octreotide on the other hand has also been 
observed in subgroups of human tumors. In a small 
subgroup of insulinomas, carcinoids, medullary 
thyroid carcinomas, ovarian cancers and GH- 
secreting pituitary adenomas, no binding of [l*?- 
Tyr3]octreotide could be demonstrated by autoradio- 
graphy, while binding sites for SS14 and SS28 were 
present [18,19]. In general, however, a good 
correlation exists between the absence or presence 
of binding sites for somatostatin and the absence or 
presence of a clinical beneficial effect of octreotide 
in patients treated with the drug [12]. The above 
data suggest he presence of multiple SS-R subtypes 
in human tumors showing peptide specificities. 
Schally’s group also provided evidence for SS-R 
subtypes in human cancers. They showed in 
membrane preparations of human breast and 
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ovarian cancers and of several human pancreatic 
adenocarcinomas that RC-160 has a considerable 
higher affinity for SSlCbinding sites than does 
octreotide [U]. These latter data also suggest that 
among different octapeptide analogs of octreotide, 
there may be, in certain cases, a differential binding 
to SS-R subtypes. 
Cross-linking studies. Cross-linking is a bio- 
chemical method to study molecular forms of SS- 
Rs. With this technique, radiolabeled ligands are 
covalently coupled to receptor proteins. The 
radiolabeled ligand-receptor complex can be ana- 
lyzed further by chromatography or by poly- 
acrylamide gel electrophoresis followed by autoradio- 
graphy. The SS-Rs detected by this technique vary 
considerably in molecular mass. A recent overview 
by Rens-Domiano and Reisine [28] shows that the 
molecular mass of SS-R ranges from 27 to 228 kDa. 
It is at present unclear what causes this heterogeneity 
in molecular mass. The existence of more than one 
receptor subtype has already been outlined above. 
It is also possible that the cross-linking technique 
itself introduces artifacts, especially when small 
peptide analogs are used as ligands. It is known that 
the properties of the cross-linking agents (i.e. spacer- 
arm length and hydrophobicity), as well as the 
composition and length of the ligand, influence the 
effectiveness of the reaction. Notwithstanding, size 
differences were also observed when the same tissue 
and method were used. Ligand selectivity has been 
reported by Murthy et LIE. [29] and Pate1 et al. [30]. 
Tyr3-octeotide seems to have specific affinity for a 
27-kDa molecular form in AtT20 cells and in rat 
brain membrane preparations. 
The recently cloned five human SSTR genes (see 
below) all encode proteins with estimated molecular 
masses of approximately 39 to 46 kDa. Post- 
translational modifications like sugar chain addition 
and proteolytic processing are known to influence 
the molecular weight of proteins considerably, 
thereby affecting the mobility of proteins in SDS- 
PAGE. Studies by Eppler et aE. [31] have 
demonstrated that approximately half of the apparent 
molecular weight of the SS-R present in GH& cells 
is due to covalently bound carbohydrate. 
Potential sites for the attachment of N-linked 
carbohydrate side chains (-Asn-Xaa-Ser/Thr, Xaa 
being any amino acid except proline) are present in 
the deduced amino acid sequences of the cloned 
SSTRs. However, not all potential glycosylation 
sites are used. There are, for instance, attachment 
sites for sugar chains located in the signal peptide 
sequence and in a transmembrane spanning domain. 
It is unlikely that these sites will be glycosylated in 
vivo. Sugar chain addition could be of functional 
significance for the structure of the ligand binding 
site. Rens-Domiano and Reisine [32] found a reduced 
affinity for the iodinated somatostatin analog MK- 
678 after desialylation of brain SS-Rs and AtT20 cell 
SS-Rs. The role of each individual glycosylation site 
can be established in future studies via site-directed 
mutagenesis followed by expression of the mutant 
DNA construct. 
Because the different molecular forms of the SS- 
R may represent different SSTR subtypes or 
processing variants of one SSTR subtype, the 
production of subtype-specific antibodies seems 
necessary to further understand and match the data 
derived from the molecular cloning and the cross- 
linking studies. Metabolic labeling in combination 
with immunoprecipitation studies will give a 
more precise insight into the biosynthesis and 
posttranslational modifications of SSTRs. A recent 
report mentions the production of a polyclonal 
antiserum raised against a synthetic peptide that 
codes for a specific part of the human SSTR2 
sequence [33]. 
Although the presence of different SS-R proteins 
has been studied extensively by the method of cross- 
linking in a variety of normal tissues [28], much less 
is known with respect to different SS-R proteins in 
human tumors. In human breast tumors, the 
somatostatin analog BIM-23014 complexed with 
three distinct SS-R proteins of 27, 42 and 57 kDa, 
while there was a considerable heterogeneity among 
the tumor specimens in the expression of the different 
proteins [34,35]. A significant positive correlation 
was found between the absence of sex steroid 
receptors and the simultaneous presence of the three 
BIM-23014 binding receptor proteins [34]. 
Molecular biology. From the above data it is clear 
that in both normal tissues (i.e. brain) and tumorous 
tissues (i.e. human insulinomas) at least more than 
one SS-R subtype is present. This concept was 
confirmed recently by the cloning of five different 
human, mouse and rat SSTR subtypes (SSTRl-5). 
Because this review deals with the clinical use of 
somatostatin analogs in relation to SSTR subtypes, 
and differences have been reported in binding 
characteristics between the same human and rat 
SSTR subtypes, we will focus on the five human 
SSTR (hSSTR) subtypes only. The five hSSTR 
subtypes consisting of 391, 369, 418, 388 and 363 
amino acids, respectively, show an amino acid 
identity ranging from 42 to 60% [36]. hSSTR1, 
hSSTR2, hSSTR3, hSSTR4 and hSSTR5 have been 
shown to be localized on chromosomes 14q13,17q24, 
22q13.1, 20 and 16, respectively [37-40]. In another 
study, Yasuda et al. reported localization of the 
hSSTR5 subtype to chromosome 20~11.2 [41]. 
However, in this study an hSSTR5 genomic 
clone isolated from a human genomic library by 
hybridization with a polymerase chain reaction- 
generated fragment of the rat SSTR4 gene [42] was 
used and may therefore be considered as an hSSTR4 
clone. 
Table 1 summarizes some characteristics of the 
five hSSTR subtypes. Certainly more information 
will become available in the near future. Initially it 
seemed that the different hSSTR subtypes were 
differentially coupled to adenylate cyclase [38,43- 
461. However, it is now clear that all five SSTR 
subtypes are functionally coupled to adenylate 
cyclase via a pertussis toxin-sensitive G-protein- 
coupled mechanism. Kaupmann et al. [47] recently 
demonstrated that somatostatin (analogs) inhibited 
forskolin-induced CAMP formation in HEK 293 
human embryonal kidney cells stably expressing the 
hSSTR1-4 subtypes. The inhibition of CAMP 
formation was pertussis toxin sensitive, indicating 
the coupling of hSSTR1-4 to pertussis toxin-sensitive 
G-proteins. In addition, Pate1 et al. [48] established 
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stably transfected CHO-Kl cells expressing the 
human genes for SSTRl-5. These five expressed 
hSSTRs all bound SS14 and SS28 with high affinity, 
and both SS14 and SS28 inhibited forskolin- 
stimulated CAMP accumulation with ED~,, values 
comparable to their binding affinities for the 
individual hSSTR subtypes. Pretreatment of the cells 
with pertussis toxin resulted in a marked reduction 
(30-70%) of [‘251]LTI SS28 binding to the five 
receptors, again suggesting that all five hSSTR 
subtypes are coupled to adenylyl cyclase via pertussis 
toxin-sensitive G-proteins. Recently, Tomura et al. 
[49] have shown that activation of the human SSTRl- 
5 subtypes may also be linked to phospholipase C 
stimulation and Ca2+ mobilization. The order of 
potency for somatostatin-induced inositol phosphate 
production was hSSTR5 > hSSTR2 > hSSTR3 > 
hSSTR4 > hSSTR1 [50]. In addition, they found 
that inhibition of CAMP formation could be reversed 
by pertussis toxin, whereas SS-induced activation of 
phospholipase C and Ca2+ mobilization was blocked 
only partially by pertussis toxin in hSSTR2, hSSTR3 
and hSSTR5 transfected COS-7 cells, indicating that 
both pertussis toxin-sensitive and -insensitive GTP- 
binding proteins may be linked to one hSSTR 
subtype. These investigators suggested that, similar 
to receptors for thyrotropin, luteinizing hormone, 
tachykinin and calcitonin, one human SSTR subtype 
may also be linked to more than one effector system 
[49,50]. This is also evident from the observations 
of Buscail et al. [51], who showed that both 
octreotide and RC-160 caused stimulation of tyrosine 
phosphatase activity in COS-7 cells transiently 
expressing hSSTR2, while RC-160 but not octreotide 
also stimulated phosphatase activity in cells 
transfected with the hSSTR1 subtype. In the same 
study, it was shown that in NIH 3T3 cells stably 
expressing hSSTR1 or 2, both RC-160 and octreotide 
inhibited bFGF- and bFGF- or FBS-stimulated cell 
proliferation, respectively, with RC-160 being slightly 
more efficacious than octreotide [51]. 
Despite the fact that there is a relatively high 
homology in amino acid identity, a common link to 
adenylyl cyclase activity, a common G-protein 
coupling, and high-affinity binding of SS14 and SS28 
to all hSSTR subtypes [47,48], several differences 
have been observed thus far in the binding affinities 
of structural analogs of somatostatin to the hSSTRl- 
5 subtypes. As has been mentioned before, all five 
hSSTR subtypes bind SS14 and SS28 with high 
affinity. Octreotide binds with high affinity to the 
hSSTR2 subtype and binds with moderate affinity 
to the hSSTR3 [44] and hSSTR5 subtypes ([36,38]; 
Table 1). However, this somatostatin analog shows 
no binding to the hSSTR1 [45,52] and hSSTR4 
[36,53] subtypes. In several studies (although less 
extensively studied than octreotide), binding of RC- 
160 and BIM-23014 to human SSTR subtypes was 
investigated. RC-160 has a very low affinity, although 
higher than that of octreotide, for the hSSTR4 
subtype [36,53], while it shows a higher affinity 
(approximately 2- to g-fold) in comparison with 
octreotide for the hSSTR5 subtype [36, 381. This 
higher affinity of RC-160 as compared with octreotide 
has also been demonstrated for the hSSTR1 and 2 
subtypes (2- and 3-fold respectively; [51]). In the 
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Table 2. Time-dependent binding and internalization of [‘251-Ty$]octreotide by cultured 
human carcinoid cells 
Membrane-bound 
Internalized 
Incubation 
time (hr) 
1 
4 
1 
4 
[lZI-Ty?]Octreotide (% dose) 
Control Octreotide (1 PM) 
0.78 2 0.01 0.62 k 0.04* 
1.10 -+ 0.02 0.59 ” 0.01* 
0.63 k 0.07 0.14 ” 0.06* 
2.33 k 0.06 0.33 ?_ 0.03” 
Human carcinoid cells were incubated with approximately 0.1 nM [?-Tyti]octreotide 
in the presence or absence of 1 PM unlabeled octreotide to determine specificity of 
membrane binding and internalization. At the end of the indicated incubation periods, 
membrane-bound and internalized radioactivity was determined by acid-stripping. 
Values are means t SEM, N = 4 wells per group. 
* P < 0.01 vs control. 
study by Panetta et al. [38], BIM-23014 also 
displaced1251-LTT-SS28 binding to the hSSTR5 
subtype with a 5-fold higher potency than octreotide. 
The binding characteristic of the somatostatin analog 
MK-678 to hSSTR5 was similar to that of octreotide 
1381. 
Raynor et al. [52] showed in extensive studies that 
BIM-23014 and octreotide possess a very low affinity 
for the hSSTR1 subtype and a relative high affinity 
(1.6 to 5.6 nM) for the mouse SSTR2 and 3 subtypes. 
Since octreotide binds to the human SSTR3 sub- 
type with an approximately 6-fold lower affinity, 
this again emphasizes that care must be taken with 
the extrapolation of ligand-binding data of mouse 
and rat SSTR subtypes to the human situation. 
Interestingly, Raynor et al. [52] also found that some 
linear analogs of somatostatin selectively bound to 
SSTR subtypes with subnanomolar affinities, whereas 
CGP 23966-like compounds (structure: cyclo[Ahep- 
Lys-Asn-Phe-Phe-Trp-Lys-Thr-Tyr-Thr-Ser]) bound 
to the hSSTR1 subtype, but not to the mouse SSTR2 
subtype [45]. In addition, it was found that CGP- 
23966 bound with high affinity to the hSSTR3 
subtype [44]. Therefore, studies directed to the 
development of somatostatin analogs, other than 
octapeptide analogs, may result in new classes of 
somatostatin analogs that might be of therapeutic 
value in the treatment of human tumors not 
expressing the hSSTR2 subtype, which has a high 
affinity for the somatostatin analogs octreotide, 
BIM-23014 and RC-160. Much of the therapeutic 
value of new agents will also depend on their 
pharmacokinetic properties, however. Depending 
on these properties, such analogs may be of 
therapeutic value in the treatment of those tumors 
that show no binding of octreotide, RC-160 and 
BIM-23014. 
Taken together, these data indicate that there may 
be relative differences (up to lo-fold) in binding 
affinities to SSTRl-5 subtypes among the three 
octapeptide somatostatin analogs available for 
clinical use now. It is also clear that none of these 
analogs binds with high affinity to the hSSTR1, 
hSSTR3 and hSSTR4 subtypes, whereas all bind 
hSSTR2 and hSSTR5 with a high and relatively high 
affinity, respectively. 
Somatostatin receptor subtype expression in human 
tumors 
There is a limited number of studies, thus far, 
showing the expression of SSTR subtypes in human 
tumors. Greenman and Melmed [54] showed 
heterogeneous expression of the hSSTR1 and 
hSSTR2 subtypes in human pituitary tumors using 
RNAse protection assays. They found that hSSTR1 
and hSSTR2 were expressed, respectively, in 3 of 7 
and 9 of 10 GH-secreting pituitary adenomas, 4 of 
5 and 0 of 5 prolactinomas, 1 of 9 and 5 of 9 non- 
functioning adenomas, and in 1 of 3 and 0 of 3 
ACTH-secreting tumors. They also found that two 
acromegalic patients who responded to octreotide 
therapy exclusively expressed the hSSTR2 subtype 
in their tumors, suggesting that the hSSTR2 subtype 
mediates the antihormonal action of octreotide in 
these tumors. In this respect, the observation by 
Raynor et al. [52] that the potencies of various 
somatostatin agonists to inhibit growth hormone 
secretion in vitro were highly correlated with their 
potencies to inhibit radioligand binding to the mouse 
SSTR2 receptor, but not to the hSSTR1 or mouse 
SSTR3 subtype, is of particular interest. In the non- 
functioning pituitary adenomas, the role of the 
hSSTR2 subtype is less clear, although it has been 
shown recently that octreotide may also have 
an inhibitory action on gonadotrophin and/or 
gonadotrophin-subunit secretion by clinically non- 
functioning pituitary adenomas in vivo and in vitro 
[55,56]. Panetta et al.* reported the presence of 
hSSTR2 and hSSTR3, but not hSSTR5 mRNA in a 
GH-adenoma, a prolactinoma, and one of two 
chromophobe adenomas. The other chromophobe 
adenoma did not express the hSSTR2,3 or 5 subtype. 
hSSTR1 and hSSTR4 expression was not tested. 
The importance of the hSSTR2 subtype in 
mediating the clinical effects of octreotide is further 
substantiated by a recent study by Kubota et al. [57]. 
These investigators showed, by using RT-PCR, the 
* Panetta R, Kent G, Greenwood M and Pate1 YC, 
Normal pituitary and pituitary tumor cells express multiple 
somatostatin receptor (SSTR) subtype genes. Program & 
Abstracts of the 75th Annual Meeting of the Endocrine 
Society, Abstr. No. 1441, 1993. 
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expression of hSSTR1, hSSTR2, hSSTR3 and 
hSSTR4 in two cases of glucagonoma and its 
metastatic lymph node in one case. In addition, a 
heterogeneous expression of these hSSTR subtypes 
was found in four insulinomas. Whereas all 
insulinomas showed expression of hSSTR1 and 
hSSTR4, hSSTR2 was not detected in one case, and 
hSSTR3 was absent in two cases. One carcinoid 
expressed hSSTR1 and hSSTR4 only, while three 
pheochromocytomas expressed the hSSTR1 and 
hSSTR2 subtype only. None of the tumor samples 
showed expression of the hSSTR5 subtype. Most 
important, these investigators also showed that 
urinary S-hydroxyindole acetic acid (5HIAA) 
excretion in the patient with a metastatic carcinoid 
lacking hSSTR2 expression was not lowered by 
octreotide treatment, while octreotide treatment 
lowered plasma glucagon levels in the patient with 
an hSSTR2 positive glucagonoma. This again 
strongly suggests that the efficacy of octreotide 
treatment may depend, at least in part, on the 
expression of hSSTR2 in tumors [57]. It should be 
noted, however, that amplification by RT-PCR of 
hSSTR subtype mRNAs from contaminating normal 
tissues cannot be excluded completely in these 
studies. Studies using in situ hybridization for the 
detection of hSSTR subtype mRNAs in tumor slices 
may help to answer this question. Of special 
importance in this respect is that Reubi et al. [58] 
recently demonstrated the presence of somatostatin 
receptors in veins surrounding different types of 
human cancer tissue. Using in situ hybridization 
histochemistry, Reubi et al. [59] studied hSSTR1, 
hSSTR2 and hSSTR3 mRNA expression in 55 human 
primary tumors. Most abundantly expressed was the 
hSSTR2 subtype. In all pituitary adenomas, 
meningiomas, neuroblastomas, breast tumors and 
small cell lung cancers, and in a majority of GEP 
tumors and lymphomas, hSSTR2 mRNA expression 
was found. hSSTR1 and hSSTR3 mRNA expression 
was observed less frequently, but most regularly 
found in GEP tumors, medullary thyroid cancers 
and ovarian cancers. In general, a good correlation 
was seen between the presence of hSSTR2 mRNA 
and binding of [1251-Tyr3]octreotide, using receptor 
autoradiography [59]. 
An intriguing question remains however: what is 
the functional role of the other hSSTR subtypes that 
are also expressed in part of the human tumors? It 
is clear that the development of new somatostatin 
analogs with a more selective action to the hSSTR1, 
3,4 and 5 subtype is needed to answer this question. 
In several human and rodent solid transplantable 
tumors and in tumor cell lines (i.e. lung, breast, 
colon, pancreas and prostate origin), Eden and 
Taylor [60] showed expression of the hSSTR2 
subtype in all tumors, while there was a differential 
expression of the hSSTR1 and hSSTR3 subtypes, as 
determined by RT-PCR. In breast tumor cell lines 
such as MCF7, MDA MB231, and ZR-75-1, 
expressing solely the hSSTR2 subtype [60], octreotide 
and BIM-23014 were shown to inhibit cell pro- 
liferation in other studies [61-66]. It is not clear, 
however, whether octreotide in these cell lines 
mediates an indirect (via the inhibition of the 
secretion of autocrine/paracrine growth factors, 
hSSTR2-mediated?) or a direct cell growth inhibitory 
effect. 
Functional studies with somatostatin analogs: Relation 
to somatostatin receptor subtypes 
SS-Rs have been shown to be linked to different 
intracellular effector systems such as adenylyl 
cyclase, ion channels and phosphatases [3ll]. It is 
evident that somatostatin (analogs) may have both 
antihormonal and antiproliferative effects in a variety 
of normal and tumorous cell systems [12]. The 
possible mechanisms of action of the tumor growth 
inhibitory effects by somatostatin analogs have been 
reviewed extensively before [12,67]. While the 
inhibitory effects of somatostatin (analogs) on 
adenylyl cyclase activity and Ca2+ influxes are linked 
to inhibition of hormone secretion [30], the 
mechanism of action of the direct, SS-R-mediated 
antiproliferative effects of somatostatin analogs is 
less clear. Both CAMP-dependent and -independent 
and pertussis toxin-sensitive and -insensitive mech- 
anisms have been proposed to be involved in direct, 
SS-R-mediated cell growth inhibitory effects in 
different cell systems [68-701. Moreover, Liebow et 
al. [71] showed that the somatostatin analog RC- 
160, but not octreotide, inhibited proliferation of 
MiaPaCa-2 pancreatic tumor cells via stimulation 
of a tyrosine phosphatase, thereby promoting 
dephosphorylation of the epidermal growth factor 
(EGF) receptor. On the basis of the discrepancy 
between the effects of RC-160 and octreotide, it was 
concluded that the antihormonal and antiproliferative 
effects by somatostatin may be mediated via different 
SS-Rs [71]. Other studies, however, have shown that 
octreotide can also stimulate phosphatase activity 
[72]. We showed in 7315b rat prolactin secreting 
pituitary tumor cells a dissociation between the 
antihormonal and antiproliferative effects induced 
by octreotide [70]. Freshly dispersed 7315b tumor 
cells do not express receptors for octreotide, while 
the number of SS-R rapidly increased during 
culturing of the cells in medium containing 10% 
FBS. At a low SS-R number, only antihormonal 
effects were observed, whereas at a higher SS-R 
number both antihormonal and antiproliferative 
effects of octreotide were found. Although there 
was a significant positive correlation between the 
inhibitory effect of octreotide on cell proliferation 
and the number of SS-R on 7315b tumor cells, the 
involvement of different SSTR subtypes could not 
be excluded [70]. Recently, we found that SS-R 
expression in 7315b tumor cells is highly estrogen 
dependent and that two major molecular forms of 
the SS-R (30 and 57 kDa), as determined by cross- 
linking of [1251-Ty8]octreotide to its receptor, were 
all stimulated by E2*. The presence of different 
molecular forms of the SS-R may represent different 
processing variants of the same SSTR or different 
SSTR subtypes (see section on cross-linking studies). 
In addition to this stimulatory effect of Ez on SS-R 
expression, which has also been observed in normal 
rat pituitary cells [73,74], glucocorticoids have a 
potent down-regulating effect on SS-R expression in 
* Visser-Wisselaar et al., Manuscript submitted for 
publication. 
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pituitary tumor cells [75]; thyroid hormones also 
may affect the number of SS-Rs [76]. Whether these 
hormones exert similar effects on SS-R expression 
in non-pituitary tumor cells is unknown. Finally, SS- 
R expression may undergo either homologous down- 
regulation after exposure to somatostatin as has 
been shown in AtT20 mouse pituitary tumor cells 
[77], or homologous up-regulation as has been shown 
in GH&, rat pituitary tumor cells [78], whereas in 
uiuo treatment of experimental tumor models with 
somatostatin analogs may also result in an increased 
number of somatostatin binding sites [79]. It would 
be of interest to know whether this up-regulation 
and/or down-regulation of SS-R is related to a 
particular SSTR subtype(s). 
Finally, when studying the effects of somatostatin 
and somatostatin analogs on cell proliferation, other 
interesting observations have been made. In different 
cell systems such as rat mesangial cells [SO], human 
hepatoma cells [69] and human pancreatic carcinoid 
cells [Sl], both inhibitory and stimulatory effects 
by somatostatin (analogs) have been observed, 
depending on the culture conditions. In the absence 
of growth-stimulatory factors (i.e. FBS or insulin), 
stimulatory effects by somatostatin (analogs) are 
observed, whereas in FBS- or insulin-stimulated 
cultures predominantly inhibitory effects are seen. 
This strong dependency of the cell growth inhibitory 
effect by somatostatin (analogs) on the hormonal 
environment of the cells is also seen in human breast 
cancer cells [61]. In human meningioma tumor cell 
cultures, Koper et al. [82] also found a stimulatory 
effect of the somatostatin analog octreotide on cell 
proliferation. Somatostatin inhibited forskolin- 
stimulated CAMP formation in membrane prep- 
arations of the meningiomas, and it was hypothesized 
that stimulation by somatostatin (analogs) of the 
proliferation of human meningioma cells in vitro 
may be mediated via interference in the autocrine 
negative control of tumor cell growth due to 
inhibition of intracellular CAMP levels. In different 
human follicular and papillary carcinoma cell lines, 
variable effects have been reported of the effects of 
the somatostatin analogs octreotide and MK-678 on 
cell proliferation [83]. Whereas MK-678 inhibited 
cell proliferation in one follicular carcinoma cell 
line, octreotide induced a stimulatory effect on the 
same cell line. In a papillary carcinoma cell line, 
MK-678 significantly inhibited cell growth in a 
concentration-dependent manner, while the same 
cells showed a biphasic response to octreotide with 
an inhibition of cell proliferation at 0.2 to 10nM 
and no significant effect on cell proliferation at 
higher concentrations. Finally, these investigators 
found that thyroid-stimulating hormone (TSH) and 
EGF altered the concentration-response relationship 
of MK-678 on the growth of another follicular 
carcinoma cell line. Taken together, it might be 
speculated that SSTR subtype expression is highly 
sensitive to regulatory effects of hormones, growth 
factors and/or steroid hormones, resulting in 
stimulatory effects as well as inhibitory effects by 
somatostatin (analogs) on the same cell type. 
We recently compared the effects of octreotide, 
BIM-23014 and RC-160 on hormone release by 
cultured cells from human GH-secreting pituitary 
adenomas, from one gastrinoma, and from normal 
rat anterior pituitary cells [84]. We found that RC- 
160 was significantly more potent in its inhibitory 
effect on hormone release as compared with 
octreotide and BIM-23014 in all three cell systems. 
It is still unclear at present whether the difference 
between the hormone release inhibitory effects of 
these analogs is caused by interactions via different 
SSTR subtypes. However, our data may be in 
accordance with several reports of a higher affinity 
of RC-160 as compared with octreotide for certain 
hSSTR subtypes. 
At present, it is also unclear which hSSTR subtype 
mediates the antiproliferative (or proliferative) 
effects of somatostatin analogs such as octreotide, 
BIM-23014 and RC-160. Since the hSSTR2 subtype, 
to which these analogs bind with high affinity, seems 
to be coupled to both inhibition of adenylyl cyclase 
activity and stimulation of phosphatase activity, this 
hSSTR subtype may be a candidate for mediating 
both effects. The hSSTR5 subtype, which is also 
coupled to adenylyl cyclase activity and which binds 
octreotide and RC-160 with a relative high affinity, 
may also be a candidate in CAMP-dependent 
inhibition of cell proliferation. However, the 
hSSTR5 subtype was not expressed in insulinomas, 
gastrinomas and carcinoids [57]. In the study by 
Greenman and Melmed [54], no correlation was 
found between SSTR subtype expression and tumor 
size of human pituitary adenomas. However, the 
four non-functioning adenomas and the GH- 
secreting tumor that did not express hSSTR1 or 2 
(see above) were particularly large and invasive. 
Therefore, again the central question at this time 
remains: what is the functional role of the hSSTR 
subtypes, other than the hSSTR2 subtype, in this 
respect? 
Somatostatin receptor-mediated internalization of 
somatostatin analogs: Relation to somatostatin 
receptor subtypes 
Receptor-mediated endocytosis of SS14 or SS28 
has been demonstrated in normal and tumorous rat 
pituitary cells and in rat islet cells [85-921. On the 
other hand, Presky and Schonbrunn [93] and Sullivan 
and Schonbrunn [94] found that [1251-Tyr1]SS14 and 
[1251-Tyr11]SS14arenot rapidly internalized, probably 
due to a rapid degradation of these radioligands by 
membrane proteases, in GH& rat pituitary tumor 
cells and in RINmSF insulinoma cells, respectively. 
We recently found that the stable somatostatin 
analog Tyr3-octreotide was rapidly internalized in a 
high amount by AtT20 mouse pituitary tumor cells 
and in human GH-secreting pituitary adenoma 
cells*. In addition, we found that cultured cells from 
a human carcinoid also internalized this somatostatin 
analog to a high extent (2% of the dose of [lZsI- 
Tyr3]octreotide added, after 4 hr of incubation; 
Table 2). Internalization of octreotide may well 
explain the rather long residence time of radioactivity 
on human tumors in viva in SS-R scintigraphy 
[12,95-971. A high rate of internalization is also of 
special importance when radiotherapy of certain SS- 
R-positive human cancers with (Y- or Pemitting 
* Hofland et al., Manuscript submitted for publication. 
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isotopes coupled to somatostatin analogs is con- 
sidered [12,20,98]. It would be of interest to know 
which hSSTR subtype(s) shows internalization in 
order to develop somatostatin analogs with high 
affinity for this particular subtype(s) that can be used 
for radiotherapy, and to investigate whether it is 
possible to (transiently) up-regulate the expression 
of this SSTR subtype(s) in order to improve the 
results of in viuo SS-R scintigraphy as well as 
the effects of radiotherapy using radiolabeled 
somatostatin analogs. 
As has been discussed above, at least five different 
human SSTR subtypes have been cloned. All 
subtypes bind SS14 and SS28 with high affinity, 
whereas their affinity for numerous somatostatin 
analogs differs considerably. Octreotide binds with 
high affinity to the SSTR2 subtype, while this analog 
has a relatively high affinity to SSTR3 and SSTR.5 
and shows no binding to SSTR subtypes 1 and 4. At 
present, it is unclear which SSTR subtype is involved 
in receptor-mediated endocytosis. Coupling to G- 
proteins seems to play a major role in agonist- 
induced receptor internalization [99]. Of interest in 
this respect is that the hSSTR2, hSSTR3 and hSSTR5 
subtypes are linked to both pertussis toxin-sensitive 
and -insensitive GTP-binding proteins [49,50]. 
Future prospects 
In conclusion, the recent cloning of at least five 
different somatostatin receptor subtypes has provided 
a major tool to study hSSTR subtype expression in 
human tumors. Furthermore, studies concerning the 
coupling of second messenger systems to hSSTR 
subtypes, as well as investigations linking hSSTR 
subtype expression to their function (i.e. anti- 
hormonal and antiproliferative effects), will give 
new insights into the functional role of hSSTR 
subtypes in human tumors. Finally, the development 
of new classes of somatostatin analogs with specificity 
to particular hSSTR subtypes may provide us with 
new drugs for the treatment of patients with tumors 
carrying SSTRs with low affinity for octapeptide 
analogs such as octreotide, BIM-23014 and RC-160. 
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